Table 2 Risk factors associated with prolonged hospital LOS.

Demographic and clinical characteristics

Disease severity status

0.78 (0.28–2.16)

0.64

–

Male sex (vs female)

0.38 (0.14–0.96)

0.04

0.19 (0.05–0.63)

0.010

Age, years

1.01 (0.98–1.03)

0.64

–

Exposure history to Wuhan

1.44 (0.58–3.62)

0.44

–

Source of patients

2.50 (0.71–10.17)

0.17

5.57 (0.88–47.14)

0.084

Smoker (vs non-smoker)

0.45 (0.02–4.87)

0.52

–

Fever

5.29 (1.21–36.88)

0.04

8.27 (1.47–72.16)

0.028

Cough

1.14 (0.44–2.92)

0.79

–

Myalgia

0.92 (0.11–8.00)

0.93

–

Throat pain

0.92 (0.11–8.00)

0.93

–

Fatigue

0.35 (0.07–1.36)

0.15

–

Chest congestion

1.75 (0.48–7.23)

0.41

4.01 (0.69–32.96)

0.151

Comorbidity

Hypertension

0.75 (0.22–2.52)

0.64

–

Diabetes

0.71 (0.16–2.91)

0.63

–

Chronic kidney or liver disease

1.45 (0.38–6.14)

0.59

13.73 (1.95–14,540.)

0.015

Laboratory characteristics in the first 2 days in hospital

CRP, mg/L

1.00 (0.98–1.02)

0.88

–

White blood cell count, *10⁹/L

0.99 (0.82–1.19)

0.90

–

Lymphocyte count, *10⁹/L

0.98 (0.52–1.83)

0.95

–

Neutrophil count, *10⁹/L

1.01 (0.83–1.22)

0.94

–

D-dimer, µg/ml

0.69 (0.22–1.66)

0.43

–

CD4/CD8

0.96 (0.55–1.67)

0.89

–

AST, IU/L

1.00 (0.97–1.03)

0.99

–

ALT, IU/L

1.00 (0.99–1.02)

0.91

–

Creatinine (per unit increase), µmol/L

0.97 (0.94–1.00)

0.07

0.94 (0.90–0.98)

0.007

Procalcitonin, ng/ml

0.72 (0.02–20.28)

0.83

–

IL-6, pg/ml

0.99 (0.93–1.00)

0.55

–

Glucose, mmol/L

1.00 (0.87–1.15)

0.97

–

lactate dehydrogenase, U/L

1.00 (0.99–1.00)

0.73

–

Troponin, µg/L

1.42 (0.39–6.72)

0.60

–

Total bilirubin, µmol/L

1.00 (0.94–1.06)

0.93

–

Indirect bilirubin, µmol/L

1.01 (0.91–1.12)

0.84

1.10 (0.97–1.25)

0.162

Direct bilirubin, µmol/L

1.00 (0.98–1.02)

0.88

–-

CT scan features

Ground-glass opacity

0.97 (0.83–1.11)

0.63

–

Bilateral patchy shadowing

2.11 (0.84–5.47)

0.12

3.46 (1.02–13.31)

0.055

Patchy consolidation

1.94 (0.44–10.05)

0.39

–